Hepatic Encephalopathy Pipeline Review, H2 2018 - Therapeutic Assessment of 8 Companies - ResearchAndMarkets.com

September 26, 2018

DUBLIN--(BUSINESS WIRE)--Sep 26, 2018--The “Hepatic Encephalopathy - Pipeline Review, H2 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Hepatic Encephalopathy - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Hepatic Encephalopathy (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The Hepatic Encephalopathy (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Hepatic Encephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Unknown stages are 5, 2, 2 and 1 respectively.

Hepatic Encephalopathy (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:

Introduction Report Coverage Hepatic Encephalopathy - Overview Hepatic Encephalopathy - Therapeutics Development Pipeline Overview Pipeline by Companies Products under Development by Companies Hepatic Encephalopathy - Therapeutics Assessment Assessment by Target Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Hepatic Encephalopathy - Companies Involved in Therapeutics Development AlfaSigma SpA Cosmo Pharmaceuticals NV Ferring International Center SA Gilead Sciences Inc MallInckrodt Plc Spherium Biomed SL Synlogic Inc Umecrine Cognition AB

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/gv4zxg/hepatic?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180926006032/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/26/2018 04:44 PM/DISC: 09/26/2018 04:44 PM


Update hourly